{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:42:21Z","timestamp":1777653741909,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA045800"],"award-info":[{"award-number":["R01DA045800"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In response to greater illicit fentanyl use, buprenorphine daily doses exceeding the FDA\u2019s recommended target daily dose (16\u00a0mg) and maximum suggested daily dose (24\u00a0mg) may provide better outcomes, but little is known about higher dosage prescribing patterns. To better understand buprenorphine prescribing patterns, this manuscript examines the frequency and characteristics of dispensed buprenorphine of \u2264\u200916mg, &gt;\u200916-24\u00a0mg, and &gt;\u200924\u00a0mg daily dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used IQVIA data to conduct a cross-sectional study of opioid use disorder-indicated buprenorphine prescriptions dispensed at retail pharmacies January 2019 - December 2020; categorized prescriptions as \u2264\u200916mg, &gt;\u200916 to 24\u00a0mg, and &gt;\u200924\u00a0mg daily dose; and examined overall rates and rates by patient, insurer and county characteristics, and prescriber specialty. We categorized buprenorphine prescriptions by patient sex, age cohort, primary payment source, and prescriber specialty and state and conducted univariate and bivariate analyses of buprenorphine daily dose categories overall and among clinicians frequently prescribing buprenorphine at the highest doses, &gt;\u200924\u00a0mg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Approximately 19.5% (<jats:italic>n<\/jats:italic>\u2009=\u20095,568,964) of the 28\u00a0million buprenorphine prescriptions from 68,898 clinicians were &gt;\u200916-24\u00a0mg; 2% (<jats:italic>n<\/jats:italic>\u2009=\u2009641,390) were &gt;\u200924\u00a0mg. Approximately 26% (<jats:italic>n<\/jats:italic>\u2009=\u200917,939) of clinicians wrote at least one prescription\u2009&gt;\u200924\u00a0mg; 2,780 clinicians (4% of buprenorphine prescribers) were responsible for 82.2% (<jats:italic>n<\/jats:italic>\u2009=\u2009527,597) of dispensed prescriptions\u2009&gt;\u200924\u00a0mg. 28% of prescriptions\u2009&gt;\u200924\u00a0mg written by these prescribers were cash-pay, 12.5% covered by Medicaid, and 6.7% covered by Medicare. There was no correlation between state fentanyl overdose rate and buprenorphine prescriptions\u2009&gt;\u200924\u00a0mg per 1,000,000 residents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In 2019\u20132020, fewer than 3% of dispensed buprenorphine prescriptions exceeded the FDA suggested maximum of 24\u00a0mg daily dose; 80% of the prescriptions for a\u2009&gt;\u200924\u00a0mg daily dose were written by 4% of buprenorphine prescribers. As clinicians and policymakers pay greater attention to ensuring individuals are receiving buprenorphine dosages adequate to effectively treat their opioid use disorder, the recently revised FDA recommendations may encourage such behavior. Additionally, disproportionate reliance on cash payment for higher daily doses suggests public and private insurers could facilitate access to such treatment when appropriate.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00547-0","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:16:28Z","timestamp":1744172188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl"],"prefix":"10.1186","volume":"20","author":[{"given":"Bradley D.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan K.","family":"Saloner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica S.","family":"Merlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"547_CR1","unstructured":"National Center for Health Statistics. Multiple Cause of Death 1999\u20132021. CDC WONDER Online Database. 2023. https:\/\/wonder.cdc.gov\/mcd.html. Accessed 22 January 2024."},{"issue":"6","key":"547_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","volume":"17","author":"MB Weimer","year":"2023","unstructured":"Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. ASAM Clinical considerations: Buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids. J Addict Med. 2023;17(6):632\u20139.","journal-title":"J Addict Med"},{"issue":"3","key":"547_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137\u201345.","journal-title":"Ann Intern Med"},{"issue":"5","key":"547_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","volume":"39","author":"H Samples","year":"2020","unstructured":"Samples H, Williams AR, Crystal S, Olfson M. Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid. Health Aff (Millwood). 2020;39(5):747\u201355.","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"547_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13722-024-00450-0","volume":"19","author":"KY Xu","year":"2024","unstructured":"Xu KY, Gertner AK, Greenfield SF, Williams AR, Grucza RA. Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims. Addict Sci Clin Pract. 2024;19(1):17.","journal-title":"Addict Sci Clin Pract"},{"issue":"9","key":"547_CR6","doi-asserted-by":"publisher","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","volume":"6","author":"LC Chambers","year":"2023","unstructured":"Chambers LC, Hallowell BD, Zullo AR, Paiva TJ, Berk J, Gaither R, et al. Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. JAMA Netw Open. 2023;6(9):e2334540.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"547_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","volume":"10","author":"A Kliewer","year":"2019","unstructured":"Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Levitt ES, et al. Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019;10(1):367.","journal-title":"Nat Commun"},{"issue":"6","key":"547_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","volume":"80","author":"MK Greenwald","year":"2022","unstructured":"Greenwald MK, Herring AA, Perrone J, Nelson LS, Azar P. A neuropharmacological model to explain buprenorphine induction challenges. Ann Emerg Med. 2022;80(6):509\u201324.","journal-title":"Ann Emerg Med"},{"issue":"1","key":"547_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ajad.13069","volume":"30","author":"D Antoine","year":"2021","unstructured":"Antoine D, Huhn AS, Strain EC, Turner G, Jardot J, Hammond AS, et al. Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone. Am J Addict. 2021;30(1):83\u20137.","journal-title":"Am J Addict"},{"issue":"5","key":"547_CR10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/add.14522","volume":"114","author":"A Bisaga","year":"2019","unstructured":"Bisaga A. What should clinicians do as fentanyl replaces heroin? Addiction. 2019;114(5):782\u20133.","journal-title":"Addiction"},{"key":"547_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","volume":"74","author":"SM Silverstein","year":"2019","unstructured":"Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. Everything is not right anymore: buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76\u201383.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"547_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dar.13017","volume":"39","author":"M Danilewitz","year":"2020","unstructured":"Danilewitz M, McLean M. High-dose buprenorphine for treatment of high potency opioid use disorder. Drug Alcohol Rev. 2020;39(2):135\u20137.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"547_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction"},{"key":"547_CR14","doi-asserted-by":"publisher","first-page":"108317","DOI":"10.1016\/j.drugalcdep.2020.108317","volume":"216","author":"LN Pizzicato","year":"2020","unstructured":"Pizzicato LN, Hom JK, Sun M, Johnson CC, Viner KM. Adherence to buprenorphine: an analysis of prescription drug monitoring program data. Drug Alcohol Depend. 2020;216:108317.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"547_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","volume":"17","author":"LA Grande","year":"2023","unstructured":"Grande LA, Cundiff D, Greenwald MK, Murray M, Wright TE, Martin SA. Evidence on buprenorphine dose limits: a review. J Addict Med. 2023;17(5):509\u201316.","journal-title":"J Addict Med"},{"issue":"1","key":"547_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/10550887.2011.642758","volume":"31","author":"A Fareed","year":"2012","unstructured":"Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1):8\u201318.","journal-title":"J Addict Dis"},{"issue":"4","key":"547_CR17","first-page":"727","volume":"45","author":"CJ Hayes","year":"2024","unstructured":"Hayes CJ, Martin BC, Hoggatt KJ, Cucciare MA, Hudson TJ, Gordon AJ. Average daily dose trajectories for episodes of buprenorphine treatment for opioid use disorder. Subst Use Addctn J. 2024;45(4):727\u201335.","journal-title":"Subst Use Addctn J"},{"issue":"9","key":"547_CR18","doi-asserted-by":"publisher","first-page":"e2435478","DOI":"10.1001\/jamanetworkopen.2024.35478","volume":"7","author":"S Axeen","year":"2024","unstructured":"Axeen S, Pacula R, Merlin J, Gordon A, Stein BD. Association of daily doses of buprenorphine with urgent health care utilization. JAMA Netw Open. 2024;7(9):e2435478.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"547_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0893-133X(00)00110-X","volume":"23","author":"J Zubieta","year":"2000","unstructured":"Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, et al. Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology. 2000;23(3):326\u201334.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"547_CR20","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","volume":"28","author":"MK Greenwald","year":"2003","unstructured":"Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, et al. Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"547_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.biopsych.2006.04.043","volume":"61","author":"M Greenwald","year":"2007","unstructured":"Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101\u201310.","journal-title":"Biol Psychiatry"},{"key":"547_CR22","doi-asserted-by":"publisher","first-page":"109902","DOI":"10.1016\/j.drugalcdep.2023.109902","volume":"248","author":"AJ Gordon","year":"2023","unstructured":"Gordon AJ, Saxon AJ, Kertesz S, Wyse JJ, Manhapra A, Lin LA, et al. Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug Alcohol Depend. 2023;248:109902.","journal-title":"Drug Alcohol Depend"},{"key":"547_CR23","unstructured":"IQVIA: Real World Data and Insights. https:\/\/www.iqvia.com\/solutions\/real-world-evidence\/real-world-data-and-insights. Accessed 13 July 2020."},{"key":"547_CR24","unstructured":"Prescribing Information: SUBOXONE sublingual film. Reference ID: 4756504: US Food and Drug Administration. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022410s042lbl.pdf. Accessed 6 February 2024."},{"key":"547_CR25","unstructured":"Food US, Administration D. FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder. 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-recommends-changes-labeling-transmucosal-buprenorphine-products-indicated-treat-opioid-use. Accessed 9 January 2025."},{"issue":"21","key":"547_CR26","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1001\/jama.2021.4469","volume":"325","author":"BD Stein","year":"2021","unstructured":"Stein BD, Saloner B, Schuler MS, Gurvey J, Sorbero M, Gordon AJ. Concentration of patient care among buprenorphine-prescribing clinicians in the US. JAMA. 2021;325(21):2206\u20138.","journal-title":"JAMA"},{"issue":"4","key":"547_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/1363461516660884","volume":"53","author":"S Mendoza","year":"2016","unstructured":"Mendoza S, Rivera-Cabrero AS, Hansen H. Shifting blame: Buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America. Transcult Psychiatry. 2016;53(4):465\u201387.","journal-title":"Transcult Psychiatry"},{"issue":"1","key":"547_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12875-019-1047-z","volume":"20","author":"DL Louie","year":"2019","unstructured":"Louie DL, Assefa MT, McGovern MP. Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review. BMC Fam Pract. 2019;20(1):157.","journal-title":"BMC Fam Pract"},{"key":"547_CR29","unstructured":"Medicaid, Payment CHIP, and Access Commission (MACPAC). Report to Congress: Utilization management of medication-assisted treatment in Medicaid. 2019."},{"key":"547_CR30","doi-asserted-by":"publisher","first-page":"111290","DOI":"10.1016\/j.drugalcdep.2024.111290","volume":"259","author":"MS Schuler","year":"2024","unstructured":"Schuler MS, Dick A, Gordon AJ, Saloner B, Kerber R, Stein BD. Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009\u20132018. Drug Alcohol Depend. 2024;259:111290.","journal-title":"Drug Alcohol Depend"},{"key":"547_CR31","unstructured":"Suboxone Coupons, Prices, Card S. 2024. https:\/\/rx.webmd.com\/drug-prices\/suboxone. Accessed 16 February 2024."},{"issue":"3","key":"547_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2105\/AJPH.2018.304899","volume":"109","author":"A Van Zee","year":"2019","unstructured":"Van Zee A, Fiellin DA. Proliferation of cash-only buprenorphine treatment clinics: a threat to the nation\u2019s response to the opioid crisis. Am J Public Health. 2019;109(3):393\u20134.","journal-title":"Am J Public Health"},{"issue":"2","key":"547_CR33","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/29767342231223721","volume":"45","author":"B Andraka-Christou","year":"2024","unstructured":"Andraka-Christou B, Golan OK, Williams M, Buksbaum S, Gordon AJ, Stein BD. A systematic review of state office-based buprenorphine treatment laws effective during 2022: counseling, dosage, and visit frequency requirements. Subst Use Addctn J. 2024;45(2):278\u201391.","journal-title":"Subst Use Addctn J"},{"issue":"6","key":"547_CR34","doi-asserted-by":"publisher","first-page":"e2318487","DOI":"10.1001\/jamanetworkopen.2023.18487","volume":"6","author":"MJ Nguemeni Tiako","year":"2023","unstructured":"Nguemeni Tiako MJ, Dolan A, Abrams M, Oyekanmi K, Meisel Z, Aronowitz SV. Thematic analysis of state Medicaid buprenorphine prior authorization requirements. JAMA Netw Open. 2023;6(6):e2318487.","journal-title":"JAMA Netw Open"},{"key":"547_CR35","unstructured":"Medication Treatment Guidelines for Substance Use Disorders (SUDs) - Transmucosal Buprenorphine. Medical policy no. 65.20.00.10-3: Washington State Health Care Authority. 2019. https:\/\/www.hca.wa.gov\/assets\/billers-and-providers\/MAT_buprenorphine_products.pdf. Accessed 6 February 2024."},{"issue":"5","key":"547_CR36","doi-asserted-by":"publisher","first-page":"e231102","DOI":"10.1001\/jamahealthforum.2023.1102","volume":"4","author":"BD Stein","year":"2023","unstructured":"Stein BD, Saloner BK, Golan OK, Andraka-Christou B, Andrews CM, Dick AW, et al. Association of selected state policies and requirements for buprenorphine treatment with per capita months of treatment. JAMA Health Forum. 2023;4(5):e231102.","journal-title":"JAMA Health Forum"},{"issue":"6","key":"547_CR37","first-page":"1964","volume":"49","author":"RE Clark","year":"2014","unstructured":"Clark RE, Baxter JD, Barton BA, Aweh G, O\u2019Connell E, Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014;49(6):1964\u201379.","journal-title":"Health Serv Res"},{"key":"547_CR38","doi-asserted-by":"crossref","unstructured":"Keshwani S, Maguire M, Goodin A, Lo-Ciganic W-H, Wilson DL, Hincapie-Castillo JM. Buprenorphine use trends following removal of prior authorization policies for the treatment of opioid use disorder in 2 state Medicaid programs. JAMA Health Forum. 2022;3(6).","DOI":"10.1001\/jamahealthforum.2022.1757"},{"key":"547_CR39","doi-asserted-by":"crossref","unstructured":"Pardo B, Taylor J, Caulkins J, Kilmer B, Reuter P, Stein B. The future of fentanyl and other synthetic opioids. Santa Monica, CA: RAND Corporation; 2019. https:\/\/www.rand.org\/pubs\/research_reports\/RR3117.html. Accessed December 9, 2019.","DOI":"10.7249\/RR3117"},{"key":"547_CR40","unstructured":"Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl: Providers Clinical Support System. 2023. https:\/\/pcssnow.org\/courses\/practice-based-guidelines-buprenorphine-in-the-age-of-fentanyl-pcss-guidance\/. Accessed 6 February 2024."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00547-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00547-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00547-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:16:33Z","timestamp":1744172193000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00547-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["547"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00547-0","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The corresponding author\u2019s Institutional Review Board approved the study with a waiver of consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to disclose.The manuscript represents valid work and that neither this manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"33"}}